Spotlight Growth
No Result
View All Result
Wednesday, March 22, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Kadmon Holdings, Inc. (NASDAQ: KDMN) Soars After $1.9 Billion Sanofi (NASDAQ: SNY) Takeover Deal

by admin
September 8, 2021
in Bio/Med/Pharma
0
Kadmon NASDAQ KDMN Sanofi NASDAQ SNY Merger Spotlight Growth

Kadmon NASDAQ KDMN Sanofi NASDAQ SNY Merger Spotlight Growth

Kadmon Holdings, Inc. (NASDAQ: KDMN) is engaged as a biopharmaceutical company, which is focused on the research, discovery, and development of novel therapeutics for a range of unmet medical needs. The company’s Rezurock product is an oral tablet designed to treat patients with chronic graft-versus-host disease (cGVHD).

Shares of the biopharma company are soaring 73% during early trading on Wednesday, September 8, 2021. Over the past three months, Kadmon has seen average daily volume of 3.75 million shares. However, volume of 45.17 million shares or dollar volume of $412.85 million, has already exchanged hands through the first hour of trading on Wednesday.

The biopharmaceutical company saw shares soar after the company entered into a definitive merger agreement with France’s Sanofi (NASDAQ: SNY). Kadmon shareholders will receive $9.50 per share in cash, giving the transaction a value of $1.9 billion. This represents a 79% premium compared to the closing price on September 7, 2021 and a 113% premium over the 60-day volume weighted average price.

The Kadmon acquisition comes as Sanofi looks to continue growing its general medicines core assets. The recently FDA-approved Rezurock will be added to Sanofi’s existing transplant portfolio comprised of Thymoglobulin and Mozobil. Thymoglobulin is a polyclonal, anti-human thymocyte antibody and Mozobil is a hematopoietic stem cell mobilizer.

“We are excited that Sanofi has acknowledged the value of Rezurock and the deep potential of our pipeline,” said Harlan Waksal, M.D., President and Chief Executive Officer, Kadmon. “By leveraging Sanofi’s global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster. I want to thank the entire Kadmon team, including management and the Board of Directors, and the Sanofi organization, for their ongoing commitment to patients and their caregivers.”

Disclosure: Neither Matt Rego nor Spotlight Growth have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: acquisitionbiopharmaceuticalsbiotechCNBCcommon stockday tradingemerging growthFox Businessinvestinginvesting newsinvestmentKadmonKadmon stockKDMNmedicalMergermicrocap stocksNASDAQnewspharmaceuticalspublic companyRezurockRobinhoodrobinhood stockssalesSanofiservicessmall cap companiessmall cap stockssmall capsSNYSpotlight GrowthSpotlight Growth Stocksstock marketstock traderstocksstocks to watchswing tradingtakeovertrader newstradingtreatmentwebull
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
JanOne NASDAQ JAN Sells ARCA Recycling Business Focus on Biopharma Spotlight Growth

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

March 22, 2023
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023
Axon Enterprise Logo

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

March 20, 2023

Recent News

JanOne NASDAQ JAN Sells ARCA Recycling Business Focus on Biopharma Spotlight Growth

JanOne (NASDAQ: JAN) Sells ARCA Recycling Business to VM7, Will Focus on Budding Biopharmaceuticals Business

March 22, 2023
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested